SLDB Solid Biosciences Inc

SLDB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Solid Biosciences Inc.

NEW YORK--(BUSINESS WIRE)--

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASADAQGS:SLDB) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/SLDB-Info-Request-Form-1868. There is no cost or obligation to you.

On March 14, 2018, Solid Biosciences issued a press release announcing receipt of a “notification from the U.S. Food and Drug Administration that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.” Upon this news, shares of Solid Biosciences fell from a close of $26.31 on March 14, 2018 to a close of $9.32 on March 15, 2018.

To learn more about the investigation of Solid Biosciences contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/SLDB-Info-Request-Form-1868.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
29/03/2018

Underlying

SLDBSolid Biosciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Announces Positive Feedback from Type C Meeting with...

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated with 36 participants dosed as of February 9, 2026, in Phase 1/2 trial - ...

February 9, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biote...

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website...

February 6, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and...

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 - Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled, ex-U.S. clinical trial, with dosing expected in Q1 2026 - - FA: First participant dosed in Phase 1b FALCON cli...

January 13, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dua...

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia - SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment - CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardi...

January 12, 2026 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Doses First Participant in First-in-Class Phase 1b F...

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-hum...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch